Wedbush maintains Janux Therapeutics at Outperform, raises price target to $40 from $36
1分未満で読めます
Wedbush maintained Janux Therapeutics at Outperform and raised its price target to $40 from $36, an 11.1% increase.
The price target implies an upside of 149.1% from the Nov 5 close of $16.06.
Explore more price target data and ratings for Janux Therapeutics on the Forecasts tab, and track all previous and future analyst recommendations in the dedicated News Flow.
Select reference data provided by Benzinga. This information is not a recommendation for what you should do personally and does not constitute investment advice.
記事の全文を読む
TradingView上で、アナリストによる最新のアップデート情報や、その他すべての記事に無制限でアクセスしましょう。